Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6262 ARTÍCULOS , VIENDO DEL 2536 AL 2550

Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease

Shejul PP, Doshi GM.

Cent Nerv Syst Agents Med Chem. 2024;24(1):22-44. doi: 10.2174/0118715249268627231206115942.

Glottal Insufficiency and Parkinson's Disease: A Scoping Review of Vocal Fold Medialization Procedures

Garabedian M, Keltz A, Lerner MZ, Brackett A, Leydon C.

J Voice. 2024 Oct 21:S0892-1997(24)00326-6. doi: 10.1016/j.jvoice.2024.09.034. Online ahead of print.

The Olfactory Trail of Neurodegenerative Diseases

Franco R, Garrigós C, Lillo J.

Cells. 2024 Apr 2;13(7):615. doi: 10.3390/cells13070615.

Artificial intelligence in Parkinson's disease: Early detection and diagnostic advancements

Reddy A, Reddy RP, Roghani AK, Garcia RI, Khemka S, Pattoor V, Jacob M, Reddy PH, Sehar U.

Ageing Res Rev. 2024 Aug;99:102410. doi: 10.1016/j.arr.2024.102410. Epub 2024 Jul 5.

The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease

Björklund A, Barker RA.

Brain. 2024 Jun 3;147(6):1937-1952. doi: 10.1093/brain/awae026.

Gold Nanoparticles in Parkinson's Disease Therapy: A Focus on Plant-Based Green Synthesis

Grancharova T, Simeonova S, Pilicheva B, Zagorchev P.

Cureus. 2024 Feb 22;16(2):e54671. doi: 10.7759/cureus.54671. eCollection 2024 Feb.

Calprotectin in Parkinsonian disease: Anticipation and dedication

Al-Kuraishy HM, Al-Gareeb AI, Zaidalkiani AT, Alexiou A, Papadakis M, Bahaa MM, Al-Faraga A, Batiha GE.

Ageing Res Rev. 2024 Jan;93:102143. doi: 10.1016/j.arr.2023.102143. Epub 2023 Nov 25.

PPAR agonists for the treatment of neuroinflammatory diseases

Titus C, Hoque MT, Bendayan R.

Trends Pharmacol Sci. 2024 Jan;45(1):9-23. doi: 10.1016/j.tips.2023.11.004. Epub 2023 Dec 7.

The Genetic Landscape of Sleep Disorders in Parkinson's Disease

Kalinderi K, Papaliagkas V, Fidani L.

Diagnostics (Basel). 2024 Jan 3;14(1):106. doi: 10.3390/diagnostics14010106.

The role of CD56(bright) NK cells in neurodegenerative disorders

Rodriguez-Mogeda C, van Ansenwoude CMJ, van der Molen L, Strijbis EMM, Mebius RE, de Vries HE.

J Neuroinflammation. 2024 Feb 13;21(1):48. doi: 10.1186/s12974-024-03040-8.

Long Non-Coding RNAs: New Insights in Neurodegenerative Diseases

Anilkumar AK, Vij P, Lopez S, Leslie SM, Doxtater K, Khan MM, Yallapu MM, Chauhan SC, Maestre GE, Tripathi MK.

Int J Mol Sci. 2024 Feb 14;25(4):2268. doi: 10.3390/ijms25042268.

Gold Nanoparticles in Neurological Diseases: A Review of Neuroprotection

Chiang MC, Yang YP, Nicol CJB, Wang CJ.

Int J Mol Sci. 2024 Feb 17;25(4):2360. doi: 10.3390/ijms25042360.

Shared and distinct changes in the molecular cargo of extracellular vesicles in different neurodegenerative diseases

Wiersema AF, Rennenberg A, Smith G, Varderidou-Minasian S, Pasterkamp RJ.

Cell Mol Life Sci. 2024 Dec 3;81(1):479. doi: 10.1007/s00018-024-05522-7.

Commercial symptom monitoring devices in Parkinson's disease: benefits, limitations, and trends

Rodríguez-Martín D, Pérez-López C.

Front Neurol. 2024 Dec 23;15:1470928. doi: 10.3389/fneur.2024.1470928. eCollection 2024.

Animal Approaches to Studying Risk Factors for Parkinson's Disease: A Narrative Review

Silva RH, Lopes-Silva LB, Cunha DG, Becegato M, Ribeiro AM, Santos JR.

Brain Sci. 2024 Feb 2;14(2):156. doi: 10.3390/brainsci14020156.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias